Every SEC Form 3/4/5 on record for this filer (CIK 1704317) — 5 issuers, 134 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| RPRX | Royalty Pharma plc | Director | 2025-04-21 → 2026-06-08 | 4 | — |
| BHVN | Biohaven Ltd. | Chief Executive Officer · Director | 2017-05-03 → 2026-03-03 | 39 | $27M |
| MANE | Veradermics, Inc | Director | 2026-02-03 → 2026-02-05 | 2 | $2M |
| RVNC | Revance Therapeutics, Inc. | Director | 2023-03-03 → 2025-02-06 | 5 | — |
| DNAA | Social Capital Suvretta Holdings Corp. I | Director · lapsed | 2021-06-29 → 2021-06-29 | 1 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| MANE | 2026-02-05 | Buy | 58,823 | $17.00 | $999,991 | 319,398 |
| MANE | 2026-02-05 | Buy | 58,823 | $17.00 | $999,991 | 319,398 |
3 of 5 issuers are covered and open a security page; the rest are on file here only.